Hepatotoxicity due to chenodeoxycholic acid supplementation in an infant with cerebrotendinous xanthomatosis: implications for treatment by Huidekoper, H.H. (Hidde H.) et al.
CASE REPORT
Hepatotoxicity due to chenodeoxycholic acid supplementation
in an infant with cerebrotendinous xanthomatosis: implications
for treatment
Hidde H. Huidekoper1,2 & Frédéric M. Vaz3 & Aad Verrips4 & Annet M. Bosch2
Received: 20 February 2015 /Revised: 13 June 2015 /Accepted: 16 June 2015 /Published online: 10 July 2015
# The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract We present a two-week old girl who was diagnosed
with cerebrotendinous xanthomatosis (CTX), an inborn error of
bile acid synthesis, after a diagnostic workup for convulsions
which were shown to be caused by a parechovirus encephalitis.
The diagnosis of CTX was confirmed with CYP27A1mutation
analysis. She was started on chenodeoxycholic acid (CDCA)
supplementation, which inhibits cholestanol production
through a feedback mechanism, at the advised dosage of
15 mg/kg/day. Within 6 weeks, she developed jaundice with
hepatomegaly. CDCA supplementation was stopped after
which liver size and function rapidly normalised. CDCA sup-
plementationwas then restarted andmaintained at 5mg/kg/day.
Cholestanol, liver enzymes and total bilirubin were frequently
monitored in the patient, who is now 2.8 years of age, and have
remained within normal range. Her psychomotor development
has been normal.
Conclusion: adequate metabolic control was achieved in an
infant with CTX with CDCA supplementation at a dosage of
5 mg/kg/day and was well tolerated. CDCA supplementation
at 15 mg/kg/day seems hepatotoxic in infants and should not
be used. This is relevant in view of the possible inclusion of
CTX in newborn screening programs in the near future.
What is Known:
• Cerebrotendinous xanthomatosis (CTX), an inborn error of bile acid
synthesis, is a progressive neurological disorder.
• Symptoms of CTX can be halted, and likely prevented, with
chenodeoxycholic acid (CDCA) supplementation, making CTX a good
candidate for newborn screening.
What is New:
• CDCA supplementation at the advised dosage of 15 mg/kg/day in
children seems hepatoxic in infants with CTX.
• Adequate metabolic control in an infant with CTX was achieved with
CDCA supplementation at 5 mg/kg/day and well tolerated.
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Introduction
Cerebrotendinous xanthomatosis (CTX) [OMIM #213700] is
a rare autosomal recessive disorder of bile acid synthesis
caused by the deficiency of the enzyme 27-sterol hydroxylase
(CYP27) [EC 1.14.13.15]. This results in a reduced production
of chenodeoxycholic acid (CDCA) and cholic acid (CA) and
accumulation of cholestanol and cholesterol in different tissues
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(Fig. 1). Clinical features of CTX include neonatal cholestasis,
bilateral cataract and chronic diarrhoea during childhood and
tendon xanthomas and various neuropsychiatric symptoms,
including pyramidal and cerebellar signs, peripheral neuropa-
thy and dementia, from the second decade onward [10].
The development of these symptoms can be halted or
prevented by supplementation of CDCA, which reduces bile
acid synthesis via direct inhibition of the enzyme cholesterol-
7α-hydroxylase (CYP7A1) [EC 1.14.13.17] and via negative
feedback on cholesterol biosynthesis (Fig. 1) [5, 7]. The prog-
nosis of CTX is good when therapy is started early but is less
favourable when initiated at a later age [1, 9, 11]. Because
early detection and start of treatment likely prevents symp-
toms, CTX is a good candidate for newborn screening. Al-
though a validated screening method is not yet available,
DeBarber et al. recently published a potential screening meth-
od for CTX based on the quantification of ketosterols [4].
The advised dosage of CDCA supplementation in children
with CTX is 15 mg/kg/day [9]. Here, we describe an infant
with CTX who developed toxic hepatitis with CDCA supple-
mentation at this dosage and demonstrate that adequate meta-
bolic control in infants and young children with CTX can also
be achieved with the lower dosage of 5 mg/kg/day of CDCA.
This is relevant in view of the possible inclusion of CTX in
newborn screening programs in the near future.
Case report
A girl, the second child of Dutch, non-consanguineous parents,
was born at term after an uneventful pregnancy and delivery
with a normal birth weight and normal Apgar scores. At day 8,
she presented with feeding difficulties, lethargy and temperature
instability, followed by convulsions for which continuous mid-
azolam was started. No jaundice was present at this time. Initial
workup, including full blood count, glucose, electrolytes, liver
enzymes, coagulation, total bilirubin, C-reactive protein and
blood gas analysis, only revealed prolonged coagulation times
(PT and aPTT) which could be rapidly corrected with vitamin
K. Further diagnostic workup, including blood, urine, faeces
and cerebrospinal fluid cultures and viral PCR, a cerebral MRI
and metabolic screening of plasma and urine, demonstrated a
positive parechovirus PCR in cerebrospinal fluid, blood and
faeces, consistent with the diagnosis of parechovirus encephali-
tis. Bilateral infarction of periventricular white matter without
bleeding was shown on the cerebral MRI and was attributed to
this encephalitis. After initial treatment on the pediatric intensive
care unit, she was transferred to a pediatric ward, where she
recovered without any signs of neurological sequelae. After
9 days, the girl was discharged in good clinical condition.
Coincidently, the metabolic screening demonstrated an el-
evated plasma cholestanol (21.5 μmol/L; reference range (age
0–100 days) 2.8–19.0 μmol/L), a low CDCA (0.1 mmol/L;
reference range 0.7–10.0 μmol/L) and CA (0.4 mmol/L; ref-
erence range 0.1–4.7 μmol/L) and urinary excretion of the
characteristic glucuronic acid conjugates of bile alcohols
(cholestanetetrol, pentol and hexol), consistent with the diag-
nosis of CTX. No other metabolic abnormalities were detect-
ed. Mutation analysis of CYP27A1 revealed two known mis-
sense mutations, c.1016C>T (p.Thr339Met) and c.1183C>T
(p.Arg395Cys) [10], confirming the diagnosis of CTX. The
patient was started on CDCA supplementation at the advised
dosage of 15mg/kg/day in three doses in children [9] resulting
in the initial normalisation of plasma cholestanol (15.0 μmol/
L), but 6 weeks after initiation of therapy, the patient presented
with jaundice, pruritis and mild hepatomegaly (liver palpable
Fig. 1 Bile acid synthesis in
CTX. Due to the deficiency of 27-
sterol hydroxylase (CYP27), the
production of chenodeoxycholic
acid (CDCA) and cholic acid
(CA) is reduced and cholestanol
and cholesterol accumulate.
CDCA supplementation inhibits
bile acid synthesis via negative
feedback on both the cholesterol
7α-hydroxylase pathway and on
cholesterol biosynthesis (dashed
lines), thereby preventing
cholestanol and cholesterol
accumulation
144 Eur J Pediatr (2016) 175:143–146
3 cm below right costal margin) without signs of infection.
Total bilirubin (73 μmol/L), liver transaminases (ALT 336 U/
L; AST 561 U/L) and alkaline phosphatase (647 U/L) were
markedly elevated; gamma-glutamyltransferase (68 U/L) and
coagulation times (PT 11.2 s; aPTT 20 s) were normal. Viral
hepatitis due to an Epstein-Barr virus or cytomegalovirus in-
fection was excluded. CDCA supplementation was stopped to
rule out toxic hepatitis. Plasma CDCA concentration at this
time was 467 μmol/L. After cessation of CDCA supplemen-
tation, liver size normalised within 1 month and liver enzymes
returned to normal values within 3 months. CDCA supple-
mentation was restarted at a dosage of 5 mg/kg/day, resulting
in the normalisation of plasma cholestanol (reference range
(age>100 days) 3.5–10.0 μmol/L) and a plasma CDCA con-
centration between 6 and 12 μmol/L. The urinary excretion of
CTX glucuronic acid conjugates of bile alcohols decreased to
almost undetectable. The patient has been maintained on a
CDCA dosage of 5 mg/kg/day since, and the plasma
cholestanol concentration has remained within the normal
range during 2.5 years of treatment. The patient’s growth
and psychomotor development have been normal, and no clin-
ical or neurological signs of CTX have been detected until
now (she is currently 2.8 years).
Plasma cholestanol, CDCA, ALT and total bilirubin con-
centrations before CDCA supplementation, during CDCA
supplementation at 15 mg/kg/day and 5 mg/kg/day and in
the period without treatment are shown in Fig. 2.
Discussion
Cerebrotendinous xanthomatosis (CTX) is a well-established
metabolic disorder of bile acid synthesis with serious progres-
sive neurological sequelae without treatment. Supplementation
of CDCAhas been proven effective inmitigating the symptoms
of CTX and will probably prevent the neurological phenotype
when treatment is started at an early age [1]. Therefore, CTX is
a good candidate for implementation in newborn screening
programs. Currently, screening methods are being developed
to make this feasible, and it is expected that CTX will be in-
cluded in newborn screening programs in the near future.
In this report, we demonstrate the development of toxic
hepatitis in an infant diagnosed with CTX shortly after birth
after starting CDCA supplementation at the advised dosage of
15 mg/kg/day [9]. This is supported by the fact that liver size
and function rapidly normalised after cessation of CDCA
Fig. 2 Plasma cholestanol (μmol/L), CDCA (μmol/L), ALT (U/L) and
total bilirubin (μmol/L) at diagnosis of CTX (age 1.4 weeks) during
treatment with CDCA supplementation at 15 mg/kg/day (dark shaded
area), after cessation of CDCA supplementation and during CDCA
supplementation at 5 mg/kg/day (light shaded area). The upper limit of
normal for each metabolite is also shown (dotted line)
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supplementation and that common causes for viral hepatitis in
children were ruled out. Hepatitis A to E were not excluded,
but it is highly unlikely that either one of these caused the
hepatitis as neither the patient nor her mother did receive
any blood products, hepatitis A and E are not endemic in
The Netherlands, and no trips to foreign countries were un-
dertaken. Furthermore, the potential hepatotoxic effect of
CDCA, as well as other bile acids, is well established and
has been shown to be dose dependent [8].
Although neonatal cholestasis is part of the clinical spec-
trum of CTX, it is unlikely that CTX by itself caused the
hepatitis as our patient only developed jaundice after initiation
of CDCA supplementation. However, the hepatotoxic effect
of CDCA in our patient may have been aggravated by the
accumulation of bile acid synthesis intermediates in hepato-
cytes. This would also explain the observed rise in plasma
cholestanol with the development of hepatitis. In support of
this is the observation that liver function deteriorated in an
infant who presented with giant cell hepatitis and who was
started on CDCA supplementation at a dosage of 10 mg/kg/
day under suspicion of a bile acid synthesis defect [2]. He was
later diagnosed with CTX [3].
It has been proposed that CTX in infants may be best treat-
ed with CA supplementation because of the potential hepato-
toxic effect of CDCA [6]. However, we think that supplemen-
tation of CDCA is the right choice of therapy in CTX, also in
infants, as it is a more potent stimulator of the nuclear receptor
FXR, thereby effectively inhibiting cholestanol formation
through the cholesterol 7α-hydroxylase pathway in CTX
[5]. Here, we show that CDCA supplementation at a dosage
of 5 mg/kg/day is safe and effective in an infant with CTX.
In this report, we demonstrate that adequate metabolic con-
trol in an infant with CTX was achieved with CDCA supple-
mentation at a dosage of 5 mg/kg/day and was well tolerated.
The currently advised dosage of 15 mg/kg/day of CDCA
seems hepatotoxic in infants and should not be used in young
children. This is relevant in view of the possible inclusion of
CTX in newborn screening programs in the near future.
Compliance with ethical standards
Informed consent Written informed consent was obtained from both
parents.
Conflict of Interest The authors declare that they have no competing
interests.
Funding None to report.
Authors’ contribution HHH for the treatment of patient, data collec-
tion and analysis and writing of the manuscript. FMV for the analysis of
blood and urine samples, interpretation of data and writing of the manu-
script. AV for advising on treatment (clinical expert on CTX), interpreta-
tion of data and commenting on the manuscript draft. AMB for supervis-
ing treatment, interpretation of data and commenting on the manuscript
draft.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. Berginer VM,Gross B,Morad K, Kfir N,Morkos S, Aaref S, Falik-
Zaccai TC (2009) Chronic diarrhea and juvenile cataracts: think
cerebrotendinous xanthomatosis and treat. Pediatrics 123:143–
147. doi:10.1542/peds.2008-0192
2. Clayton PT, Casteels M, Mieli-Vergani G, Lawson AM (1995)
Familial giant cell hepatitis with low bile acid concentrations and
increased urinary excretion of specific bile alcohols: a new inborn
error of bile acid synthesis? Pediatr Res 37:424–431. doi:10.1203/
00006450-199504000-00007
3. Clayton PT, Verrips A, Sistermans E, Mann A, Mieli-Vergani G,
Wevers R (2002) Mutations in the sterol 27-hydroxylase gene
(CYP27A) cause hepatitis of infancy as well as cerebrotendinous
xanthomatosis. J Inherit Metab Dis 25:501–513
4. Debarber AE, Luo J, Star-Weinstock M, Purkayastha S, Geraghty
MT, Chiang JP,Merkens LS, Pappu AS, Steiner RD (2014) A blood
test for cerebrotendinous xanthomatosis with potential for disease
detection in newborns. J Lipid Res 55:146–154. doi:10.1194/jlr.
P043273
5. Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG,
Kliewer SA, Stimmel JB, Willson TM, Zavacki AM, Moore DD
et al (1999) Bile acids: natural ligands for an orphan nuclear recep-
tor. Science 284:1365–1368
6. Pierre G, Setchell K, Blyth J, Preece MA, Chakrapani A,
McKiernan P (2008) Prospective treatment of cerebrotendinous
xanthomatosis with cholic acid therapy. J Inherit Metab Dis
31(Suppl 2):S241–S245. doi:10.1007/s10545-008-0815-z
7. Salen G,Meriwether TW,NicolauG (1975) Chenodeoxycholic acid
inhibits increased cholesterol and cholestanol synthesis in patients
with cerebrotendinous xanthomatosis. Biochem Med 14:57–74
8. Song P, Zhang Y, Klaassen CD (2011) Dose-response of five bile
acids on serum and liver bile acid concentrations and hepatotoxicty
in mice. Toxicol Sci 123:359–367. doi:10.1093/toxsci/kfr177
9. van Heijst AF, Verrips A, Wevers RA, Cruysberg JR, Renier WO,
Tolboom JJ (1998) Treatment and follow-up of children with
cerebrotendinous xanthomatosis. Eur J Pediatr 157:313–316
10. Verrips A, Hoefsloot LH, Steenbergen GC, Theelen JP,Wevers RA,
Gabreels FJ, van Engelen BG, van den Heuvel LP (2000) Clinical
and molecular genetic characteristics of patients with
cerebrotendinous xanthomatosis. Brain 123(Pt 5):908–919
11. Yahalom G, Tsabari R, Molshatzki N, Ephraty L, Cohen H, Hassin-
Baer S (2013) Neurological outcome in cerebrotendinous
xanthomatosis treated with chenodeoxycholic acid: early versus late
diagnosis. Clin Neuropharmacol 36:78–83. doi:10.1097/WNF.
0b013e318288076a
146 Eur J Pediatr (2016) 175:143–146
